Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma

Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Study ID
NCT05444088
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

  • Advanced Hepatocellular Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Adebrelimab — DRUG
    intravenous infusion
  • Bevacizumab — DRUG
    intravenous infusion
  • SHR-8068 — DRUG
    intravenous infusion

Study Details

To evaluate the tolerability and safety of SHR-8068 in combination with Adebrelimab and Bevacizumab in subjects with advanced HCC; To evaluate the efficacy of SHR-8068 in combination with Adebrelimab and Bevacizumab in subjects with advanced HCC.

Key Dates

First listed
Jul 5, 2022
Start date
Aug 2, 2022
Status verified
Jun 2024
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
129 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Adebrelimab in combination with Bevacizumab
  • Experimental: Adebrelimab in combination with Bevacizumab and SHR-8068 RP2D1
  • Experimental: Adebrelimab in combination with Bevacizumab and SHR-8068 RP2D2

Primary Outcome Measure

Dose Limiting Toxicity [ Time Frame: The observation period is 21 days after the first dose ]

Central Contacts

Related Studies